NEJM 25 June 2015 Vol 372 2533 The research articles in this week’s print NEJM are all about arcane stuff I’ve covered previously. The Clinical Practice article takes us back […]
Richard Lehman’s weekly review of medical journals
Richard Lehman’s journal review—22 June 2015
NEJM 18 June 2015 Vol 372 2387 For the first time in years, I actually handled a new printed copy of the NEJM last night. What a suave production it […]
Richard Lehman’s journal review—15 June 2015
NEJM 11 June 2015 Vol 372 2307 Here at last is a study that shows some benefit from out of hospital cardiopulmonary resuscitation. It’s not a randomised trial, since that […]
Richard Lehman’s journal review—8 June 2015
NEJM 4 Jun 2015 Vol 372 2185 If you are the sort of exciting doctor who looks after adults with acute hypoxaemic respiratory failure, here is just the article you […]
Richard Lehman’s journal review—1 June 2015
NEJM 28 May 2015 Vol 372 2087 Now that the NEJM has flagged up its position on conflicts of interest, it’s definitely a case of caveat lector—looking hard at what […]
Richard Lehman’s journal review—26 May 2015
NEJM 21 May 2015 Vol 372 2064 The NEJM has the highest reputation of any medical journal, so it’s impossible not to feel dismay when it lets its standards slip […]
Richard Lehman’s journal review—18 May 2015
NEJM 14 May 2015 Vol 372 1887 Something strange seems to be going on in the New England Journal of Medicine. This week it publishes two trials of gene therapy […]
Richard Lehman’s journal review—11 May 2015
NEJM 7 May 2015 Vol 372 1860 This week the NEJM is offering everyone a free lunch, in the form of an open access article and editorial on the theme […]
Richard Lehman’s weekly journal review—5 May 2015
NEJM 30 April 2015 Vol 372 1684 “Virtual Visits—Confronting the Challenges of Telemedicine” is a Perspective piece which starts full of optimism about the potential of telemedicine and then switches […]
Richard Lehman’s weekly journal review—27 April 2015
NEJM 23 Apr 2015 Vol 372 Last week, dear friends, we kicked off with alirocumab and evolocumab. This week it’s the turn of nivolumab, ipilimumab, and pembrolizumab. It’s driving me […]